Monopar Therapeutics — Director's Dealing 2025

Jan 3, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2024-12-31

Reporting Person: Cittadine Andrew (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-31	Common Stock	M	1790	—	Acquired	41659	Direct
2024-12-31	Common Stock	F	721	$22	Disposed	40938	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-31	Restricted Stock Units	$	M	1790	Disposed		Common Stock (1790)	Direct

Footnotes

F1: Represents shares acquired on vesting and settlement of restricted stock units.

F2: Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.

F3: On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

F4: On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.